Supporting evidence based drugs policy through epidemiology, monitoring, evidence review, intervention evaluation and primary research.
Public Health Institute (PHI) has established itself as one of the UK’s leading applied research groups. Research in this area began with the development of local monitoring systems for drug treatment and needle exchanges, and this early work informed the sophisticated national monitoring systems we see today.
In parallel streams of work, PHI’s realistic evaluation approach has helped a variety of stakeholders understand the impact that their work is having and how best to improve services. Primary research has provided insights into a variety of substance related topics, particularly in priority groups such as young people, drug injectors, and families affected by drugs.
Research undertaken by the Public Health Institute has contributed to the development of two successive UK National Drug Strategies and a number national and international guidance. PHI’s systematic reviews of evidence for the effectiveness of drug prevention interventions, and optimal provision of needle and syringe exchange programmes underpinned National Institute for Health and Clinical Excellence (NICE) guidance in these areas. Public Health Institute also coordinates the UK arm of the EMCDDA’s early warning system on psychoactive drugs and this intelligence also feeds into to UK monitoring systems.
PHI is responsible for producing estimates of the prevalence of opiate and / or crack cocaine use in England. Information about the number of people who use these drugs is key to formulating effective policies for tackling drug-related harm and also helps inform service provision at the local level. PHI also takes the lead in the EMCDDA’s problem drug use indicator, collating opiate use prevalence estimates across the four nations within the UK.
Public Health Institute has also developed research specialisms in novel psychoactive drugs (‘legal highs’). As well as coordinating the UK arm of the EU Early Warning System on Novel Psychoactive Drugs, PHI’s policy critiques, forensic analyses, and evidence reviews have contributed to international discussions on this emerging public health priority.
Drugs Case Studies
Adverse Childhood Experiences (ACEs)
A growing body of research is revealing the long-term impacts that experiences and events during childhood have on individuals’ life chances. Adverse Childhood Experiences (ACEs) such as abuse, neglect and dysfunctional home environments have been shown to be associated with …
Publications for Drugs
Papers for Drugs
Professor Marie Claire Van Hout, C Claffey, M MacLachlan, Des Crowley
Heroin Addiction And Related Clinical Problems, 19 (6). ISSN 1592-1638, 2017.
Abstract: The Irish Travelling community are identified “as a people with shared history, culture and traditions including, historically, a nomadic way of life”. The core of Travelling culture is strong family bonds which support resilience, however changing social circumstances and dislocation have contributed to significant mental and physical health issues accompanied by a steep rise in substance abuse and addiction.
Experiences of Codeine Use, Misuse and Dependence: Application of Liese and Franz’s Cognitive Developmental Model of Substance Abuse.
Professor Marie Claire Van Hout, Ian Norman, Eileen Rich, Michael Bergin
Behavioural and Cognitive Psychotherapy, 45(3), 238-252. doi:10.1017/S1352465817000030, 2017.
Abstract Misuse of codeine-containing medicines is an emerging public health issue.
Addiction. doi:10.1111/add.14065, 2017.
Abstract: Commentary to: Will growth in cryptomarket drug buying increase the harms of illicit drugs?